Drug Profile


Alternative Names: BI-201335

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Trek Therapeutics
  • Class Amides; Antivirals; Carboxylic acids; Cyclopropanes; Oligopeptides; Pyrrolidines; Quinolines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Sep 2016 Efficacy and adverse events data from a phase IIa trial in Hepatitis C released by Trek Therapeutics
  • 21 Jun 2016 Trek Therapeutics initiates a phase IIa trial for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO)
  • 01 Apr 2016 Phase-II clinical trials in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (PO) (NCT02716428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top